Sanofi Raises Earnings Again, but the Post-Dupixent Bridge Still Needs Numbers

Results vs. Consensus

The third quarter strengthens the operating case we carried into July: demand is broad enough and costs restrained enough to grow earnings despite the alliance reimbursement ending. It does not yet resolve the valuation question. The biggest commercial contributor remains Dupixent, while the assets intended to extend the franchise are years from approval.

Business EPS is a non-IFRS measure. The consensus ranges reflect different contemporaneous estimate panels. The larger profit surprise than sales surprise is consistent with unusually strong operating leverage; it should not be read as a sustainable earnings-growth rate.

Year-over-year financial performance

Sequential comparison

The sequential surge is heavily seasonal: vaccines rise from €1,150m to €3,185m as Northern Hemisphere deliveries build. The 37.6% operating margin is therefore not a sensible full-year run rate. More revealing is that gross margin nearly matched Q2 even though that quarter included a large manufacturing-provision reversal.

Revenue. Currency added 1.9 percentage points to Q3 sales growth, reversing the first-half drag. Dupixent demand, pharma launches and insulin supported the quarter, while divestments reduced growth by 0.4 points. The roughly two-point one-off contribution is a group estimate, not a disclosed Dupixent adjustment that can be subtracted drug by drug.

Margins. R&D plus selling and general expenses increased only €33m, while business gross profit rose €1,883m. That leverage more than absorbed an €865m deterioration in net other operating expense, predominantly the alliance. This directly supports our cost-discipline pillar. However, flat research spending partly reflects discontinued projects; it is not proof that a replenished late-stage portfolio will cost the same to develop.

EPS. A 1.5% lower average share count helped business EPS outgrow business net income. Higher financing expense and a 20.4% effective tax rate, versus 19.3%, worked in the other direction. The completed buyback supports the year-over-year comparison, but average shares rose to 1,200.0m from 1,196.6m in Q2, so another sequential repurchase benefit is not in our forecast.

The IFRS-to-business reconciliation

The €1,234m gap is narrower than Q2’s, but still substantial. Amortisation is the largest adjustment; litigation and other tax effects also matter. Business earnings describe the commercial engine more clearly than IFRS EPS, yet they exclude recurring acquisition-related costs in a strategy increasingly dependent on buying assets. We value business EPS at a restrained multiple for that reason as well as the patent exposure.

Segment Performance

Sanofi reports a Biopharma segment; the franchise and geographic views below explain its operating drivers. Launches overlap disease-area sales and are not an additional segment to sum into group revenue.

Dupixent: demand is intact, but the growth base changes

Dupixent contributes 39.4% of quarterly sales and €15,011m year to date. Its Q3 share is below Q2’s 44.4% because of seasonal vaccines, not a reduction in the strategic dependence. US sales reached €4,376m, up 40.2% at CER, with demand and favourable gross-to-net adjustments both contributing. More than 1.5 million patients are on treatment globally.

Assessment: The demand pillar stays ON TRACK. Wider advanced-therapy penetration supports continued expansion, but a larger comparison base and less incremental pricing benefit argue against extrapolating growth in the mid-thirties into 2027.

Launches and rare disease: the second franchise is growing

The pharma launch cohort reached €1,390m, with year-to-date sales of €3,866m. ALTUVIIIO benefited from switches away from shorter-acting factor therapies; Ayvakit continued adding patients. The wider rare-disease portfolio grew 12.6% to around €1.9bn on management’s rounded presentation. Nexviazyme growth slowed to 4.0%, while Myozyme fell 15.6%; selected supply constraints also affected the quarter.

Assessment: The existing launch portfolio remains a credible diversification engine. Our prior €5.2–5.3bn full-year launch expectation requires €1.33–1.43bn in Q4, broadly around Q3’s level. That is achievable without assuming an acceleration, although a successful commercial cohort alone does not close the post-2031 gap.

Vaccines: a better quarter than promised, not a recovery

July’s low-to-mid-teens decline warning proved too severe: sales fell 6.6%, helped by more favourable late-quarter Beyfortus buying than anticipated. Nevertheless, US Beyfortus sales fell 39.3% to €240m, including a lower central order. Influenza delivery phasing should help Q4; the full-year vaccine outlook remains a low-single-digit decline.

Assessment: The Q3 commitment was exceeded, but demand and policy risks remain. Timing relief should not be confused with reversing the weaker US immunisation outlook that drove July’s lower 2030 ambition.

Geographic mix and key KPIs

US sales represent 59.6% of the quarter. Europe’s decline and modest rest-of-world growth leave US demand and reimbursement economics disproportionately important. Currency helped this quarter, but the full-year guide still assumes a roughly 1% drag on both sales and business EPS; the translation risk has changed direction, not disappeared.

Key Topics & Management Commentary

Overall Management Tone: Management was more concrete about execution than in July, pointing to a signed alliance expansion and renewed margin commitments. Confidence in the commercial business remained high; the post-exclusivity discussion still relied on ambitions whose detailed financial bridge is deferred to December.

1. Regeneron: the promised negotiation has produced a transaction

Sanofi gains access to four long-acting antibodies for $1bn upfront and up to $7bn in additional milestones. New programmes share costs and future global profits 50:50. Regeneron leads R&D and Sanofi commercialisation; the existing Dupixent and Kevzara profit-sharing agreement does not change. The lead IL13 antibody is in phase 1, with registrational studies expected in late 2027 or early 2028.

The expanded alliance shows our ability to execute swiftly on our priorities, driven by transparent discussions and building trust as shown by the settlement of previous litigations.
— Belén Garijo, Chief Executive Officer

Assessment: This fulfils July’s relationship-repair commitment and buys scientific options, not near-term earnings. The unchanged existing profit split means our alliance-economics bear pillar remains MATERIALIZING. No value is assigned to an unapproved replacement drug in our base earnings estimate.

2. The alliance reimbursement has ended; royalties cushion rather than erase it

The net Regeneron alliance expense rose to €2,399m from €1,369m. Profit sharing increased to €2,230m, while development-cost reimbursement fell to €11m from €293m. Amvuttra licensing income rose €158m to €296m. Management expects the full-year royalty increase to offset the full-year reimbursement decline, but the H2 reimbursement headwind alone is around €500m.

Assessment: The full-year offset is consistent with a difficult quarterly comparison because benefits and headwinds arrive at different times. July’s roughly €200m net FY2027 headwind is no longer a sufficiently secure single-point assumption: management is reassessing royalty expectations following the partner’s latest update. We retain a cushion in the 2027 outlook rather than treating that offset as guaranteed.

3. Margin growth is reaffirmed, with an acquisition caveat

July did not repeat the earlier promise to grow operating income and margin in 2027. This call restores it and extends the ambition through 2030. The mechanism is explicit: the cost base should grow more slowly than sales, with strong Q4 growth alongside broadly flat operating expenses.

So we do confirm what we have confirmed in with what we have said for a few -- for some time already, which is, we will increase our BOI in absolute value next year as well as in BOI margin.
— François-Xavier Roger, Chief Financial Officer

Assessment: The missing commitment has been restored and supports Bull 3. However, the CFO limits the framework to organic growth and traditional bolt-ons; a larger acquisition with substantial development spending could change it. We do not price the margin promise as an unconditional guarantee.

4. Gross-to-net: a higher level, not a repeat growth source

Better rebate controls and data-driven provisioning have raised net realised revenue. Management separates those structural improvements from exceptional catch-ups and estimates underlying group growth at about 12%. The recurring benefit remains unsized in euros.

We will continue to do an excellent job on operational improvements and gross to net management, but don't expect that to continue to grow is my point.
— Manuela Buxo, Head of Specialty Care

Assessment: This answers part of July’s open question. Keeping a higher net price is economically valuable, but the increment cannot be added again each year. Our 2027 growth assumption is therefore below 2026 even with continued patient additions.

5. Pipeline timing makes acquired revenue more important

The new milestone table places frexalimab phase 3 data in 2028, compared with the 2027 relapsing-MS timing carried in our July note. Management explains that longer observation is needed to collect sufficient events. Riliprubart phase 3 data are now in 2027, versus the H2 2026 expectation we were monitoring. Lunsekimig’s phase 2 asthma and nasal-polyp studies met their objectives, but differentiation in asthma remains under review.

Assessment: Extending observation can improve a study’s statistical power; it is not evidence that the drug has failed. For shareholders, however, later data leave less time to establish replacement revenue before Dupixent’s product-patent expiry. The financing and execution burden shifts further toward business development.

6. R&D productivity: a narrower focus needs measurable output

The new research head outlined technical reviews across the pipeline, more integrated therapeutic-area ownership, AI-supported decisions and greater access to Chinese innovation. Immunology, rare diseases and vaccines receive most capital; assets outside those areas may be partnered, licensed out or discontinued.

So what it means is that the majority of our capital, both R&D as well as external innovation will be allocated to those therapeutic areas in focus.
— Belén Garijo, Chief Executive Officer

Assessment: Sharper allocation addresses July’s diagnosis of weak development decisions. We give no forecast credit for AI shortening trials until programme-level outcomes demonstrate it. The relevant test is more differentiated clinical assets reaching approval, not simply more projects entering phase 1.

7. Portfolio simplification removes sales before it proves its return

The proposed transfer of 20 mature medicines and three sites to Cheplapharm gives Sanofi a 26.4% equity stake. Commercial transfers are planned from Q1 2027 and full completion by Q3, subject to approvals and other conditions. Together with Medley, management expects around €1.3bn less revenue in 2027.

Both transactions will reduce our sales next year by around EUR 1.3 billion, but they allow us to focus on science and to exit margin-dilutive businesses.
— François-Xavier Roger, Chief Financial Officer

Assessment: That revenue loss is roughly 2.6% of our FY2026 sales estimate. Removing lower-margin products can raise the margin percentage while reducing profit dollars, so our forecast separately allows for underlying growth and the disposal effect. The equity consideration also differs from immediate cash available for acquisitions.

8. Cash generation creates deal capacity, not a reason to spend it

Net debt fell €3.31bn from June to September to €12.20bn, supported by €3.27bn of quarterly free cash flow. The dividend policy is reaffirmed, but management gives no deal-capacity ceiling and remains open to larger late-stage or commercial acquisitions. The October Regeneron upfront is subsequent to the September balance sheet.

Assessment: Cash generation makes a disciplined transaction possible and reduces immediate funding pressure. It does not remove the risk opened in July: paying a high price to fill a publicly visible pipeline gap. We retain Bear 5 at EMERGING pending disclosed purchase economics and integration requirements.

Guidance & Outlook

We raise our reported sales estimate to about €49.3bn and business EPS to €9.00. Using the prior-year €43.626bn sales base, 14% CER growth less roughly one percentage point of translation yields about 13% reported growth. For EPS, €7.83 grown by 16% at CER less roughly one point of translation gives approximately €9.00. These are midpoint-based analyst estimates, not precise company euro guidance.

Implied Q4: after €36.55bn of sales and €7.52 of business EPS through September, our forecast leaves roughly €12.75bn and €1.48 for Q4. Against prior-year Q4 sales of €11.303bn and EPS of €1.53, that is about 12.8% sales growth but a 3.3% EPS decline. Seasonal margin normalisation, the reimbursement loss and lower disposal gains explain why a strong annual upgrade need not produce Q4 EPS growth.

Guidance style and expectations. July’s conservatism was exposed by better vaccines and another gross-to-net benefit. The new forecast now incorporates that strength, rather than demonstrating that those surprises recur. The raise is likely to lift annual earnings expectations, but the 2027 commentary introduces less favourable pricing comparisons and disposal dilution at the same time. We would need evidence of demand-led growth through those comparisons before raising the valuation multiple.

Analyst Q&A Highlights

The 2027 pricing reset

The question distinguished competitive access from the normal US first-quarter net-price reset. Management emphasised market expansion and demand, but did not quantify next year’s net pricing.

Q: And just quickly following up on the comments around more normal trends for Dupi in 2027? Should we expect the normal step down in gross to net price in Q1 that is just the traditional seasonality?
— Matthew Weston, UBS

A: You will likely see the same Q1 adjustment that we see in the U.S. every single year. But again, demand growth will continue to stay strong also in 2027.
— Manuela Buxo, Head of Specialty Care

Assessment: The answer supports demand, not a repeat of the 2026 pricing lift. A normal Q1 adjustment and a larger base justify slower growth even without deterioration in patient uptake.

Whether the margin promise includes a large deal

The follow-up tested how much acquisition spending was embedded in management’s 2027 operating-leverage comments.

Q: One, Francois, just going back to your comment just now when you talk about the OpEx growth below sales for 2027 and '28, is that purely organic? Or are you already leaving some wiggle room here for M&A/BD that may come into the equation? So if you did something that came in R&D, can be talked into your outlook? Or would that be incremental to what you just said?
— Michael Leuchten, Jefferies

A: But once again, it's based on organic growth plus the traditional bolt-on that we have done traditionally over the last couple of years.
— François-Xavier Roger, Chief Financial Officer

Assessment: The preceding answer explicitly declined to incorporate anything more significant than a bolt-on before it is announced. The margin framework is useful for the existing business, but a major pipeline acquisition would require a fresh earnings bridge.

How much of the sales growth is exceptional

A recurring challenge sought to reconcile prescription growth with revenue and to quantify the non-recurring net-price component.

Q: So in essence, how much of a headwind is there of one-off gross to net in the base Dupixent as we go into next year?
— Graham Glyn Parry, Citi

A: I won't answer specifically for Dupixent, but be aware of the fact that we grew 14% in Q3. The underlying growth, if we exclude the one-offs is 12%, which means that between 85% and 90% of our growth is recurring, demand-driven, sustainable growth and is not linked to one-off.
— François-Xavier Roger, Chief Financial Officer

Assessment: This is a useful group-level bound, not a Dupixent revenue bridge. We use the approximate 12% underlying figure to assess earnings quality while leaving the recurring drug-level rebate benefit unquantified.

The size of the post-exclusivity revenue gap

The question asked whether the confidence in a moderate group revenue impact depended on new alliance assets or on other pipeline and deal execution.

Q: I just want to touch on the comments you made on your slides on the moderate impact on sales at Dupixent loss of exclusivity. Just to understand what gives you confidence here, is it the transition of the franchise to the new assets and the collaboration with Regeneron? Or is it execution on pipeline and be development, M&A to sort of compensate for the revenues the building blocks to basically get confidence that the top line will only only see a moderate impact.
— Thibault Boutherin, Morgan Stanley

A: And due to the alliance with Regeneron and the profit split, you can imagine that the impact on earnings is lower than our revenue. And of course, above all, we are going to preserve our -- we aim to preserve our cash flow.
— Belén Garijo, Chief Executive Officer

Assessment: Profit sharing does cushion the earnings exposure to lost sales, a counterweight to our alliance-cost concern. The answer nevertheless supplies no revenue or profit erosion curve, and retains an explicit aspiration rather than a guarantee on cash flow. December remains the test of the proposed replacement plan.

Whether more accrual benefits are still to come

The final exchange pressed on the incremental opportunity from better gross-to-net data and provisioning.

Q: I just wondered if you could give us a little bit more detail on the the data-driven gross to net management that you've introduced. Have we effectively seen the main impact? And going forward, the impact will simply be a smaller gap between volume and sales? Or is there more to come there?
— Simon Baker, Redburn

A: And as a consequence of that, we had some kind of one-off exceptional in Q3 that we talked about earlier. And I don't expect that to replicate. So not to the extent that we saw in Q3.
— François-Xavier Roger, Chief Financial Officer

Assessment: The answer constrains the forecast more clearly than the headline growth. Operational improvements can sustain the level of earnings, but the exceptional catch-up should not be treated as an additional quarterly growth driver.

What They're NOT Saying

1. No quantified post-2031 earnings bridge. A moderate revenue impact and preserved cash flow remain ambitions. There is no disclosed erosion rate, replacement-sales schedule or margin sensitivity sufficient to underwrite a higher terminal multiple.
2. No fully updated 2027 royalty offset. The CFO is awaiting revised external sales expectations; July’s net €200m reimbursement headwind cannot simply be treated as newly reaffirmed guidance.
3. No recurring gross-to-net benefit in euros. The group one-off estimate is helpful, but it cannot isolate the durable Dupixent price level or its exposure to ongoing 340B litigation.
4. No acquisition return threshold or deal-capacity ceiling. A strong investment-grade rating and dividend continuity constrain spending, but do not establish that a particular transaction creates value.
5. No completed patent test or dated update on the earlier co-formulation defence. The new long-acting alliance assets are separate development programmes, not proof that existing Dupixent exclusivity extends past the product-patent date.

Market Reaction

• Pre-print setup: SNY closed at $43.13 on October 29, down 11.0% year to date and 15.3% over twelve months, but up 4.6% over the prior thirty days. The pre-print 52-week closing range was $39.12–$52.34.
• October 30 reaction session: The ADR opened at $44.82, traded between $44.23 and $45.30, and closed at $44.34, up 2.8%. Volume was 15.1m shares, 4.5 times its 30-day average.
• Market comparison: The S&P 500 fell 1.8% that session, leaving SNY ahead by about 4.6 percentage points. The benchmark had gained 12.8% year to date entering the print.

The reaction is consistent with investors rewarding a substantial beat, another guidance raise and tangible alliance progress after a weak year. Heavy volume makes the move more consequential than a routine low-liquidity bounce, but it cannot isolate which disclosure caused the buying. The ADR also finished below its opening level; enthusiasm for better current earnings did not produce an uninterrupted re-rating.

The distinction from July is that the operating upside is now accompanied by a transaction addressing the pipeline rather than only cancellations. Yet the share price still requires only a modest multiple on our higher EPS estimate. The rally recognises execution progress without establishing that the 2031 uncertainty has been solved.

Street Perspective

Does the new alliance close the replacement gap?

Bull view: Repaired relationships and four new antibodies give Sanofi a credible route to extend its immunology franchise using an established commercial platform. The transaction demonstrates faster decisions under the new leadership.

Bear view: Early-stage antibodies may not reach market on the required timetable, and the existing profit split is unchanged. Milestone commitments consume capital that might otherwise buy closer-to-market revenue.

Our take: The agreement is progress against a specific July commitment, but it is pipeline replenishment rather than a funded revenue replacement plan. We recognise improved execution without increasing the valuation multiple.

How much of the earnings strength survives 2027?

Bull view: Strong demand, favourable mix and restrained operating expenses allow profit growth even after reimbursement ends. The recurring part of better rebate administration supports a higher earnings base.

Bear view: Exceptional pricing benefits and completed buybacks make the comparison harder; divestments reduce revenue and acquisition spending could absorb the apparent operating leverage.

Our take: The operating case is stronger than in July, but the relevant question is growth from the new base. We forecast slower 2027 EPS growth and retain room for royalty and spending disappointments.

Is acquisition capacity an asset or a liability?

Bull view: Strong cash generation and an investment-grade balance sheet can purchase later-stage assets while preserving the dividend, reducing reliance on uncertain internal research.

Bear view: A public patent deadline and a narrow set of strategic priorities weaken negotiating leverage. Commercial assets cost more precisely because their scientific risk is lower.

Our take: Capacity has value only at an acceptable price. Until a deal provides its purchase price, sustainable cash flows and financing costs, we assign no earnings uplift and keep the acquisition-risk pillar EMERGING.

Our Estimates & Valuation Framework

Forecast bridge. Our €49.3bn sales estimate and 28.5% business operating margin imply €14.05bn of FY2026 business operating income. Deducting €0.40bn of assumed net financial expense, applying a 21% tax rate and dividing by 1.20bn shares yields €8.99, rounded to our €9.00 business EPS estimate. The full-year margin rises only modestly from our prior 28% assumption despite the strong Q3 peak, because the second half loses reimbursement income and disposal gains are lower than previously expected.

After €11.688bn of operating income and €0.283bn of financial expense through September, this leaves about €2.36bn of Q4 operating income at an 18.5% margin on €12.75bn of sales. The remaining €0.117bn financing cost, a roughly 21% tax rate and 1.20bn shares imply about €1.48 Q4 EPS. This is a sharp seasonal profit decline from Q3; the guide-based annual EPS forecast therefore carries considerably less fourth-quarter leverage than the third-quarter print alone would suggest.

For 2027, our assumed 6% underlying growth on €49.3bn, less €1.3bn of divestments, gives €50.96bn. Growth slows from 2026 as pricing benefits enter the base. A 29.0% margin produces €14.78bn of operating income; deducting an assumed €0.50bn net financing cost, taxing at 21%, and dividing by 1.20bn shares yields about €9.40 EPS. The half-point margin improvement is an analyst assumption reflecting continued expense restraint after allowing for the reimbursement loss. It depends on royalty growth broadly cushioning that loss and excludes a large acquisition. Each additional €100m of net operating headwind reduces EPS by about €0.07 at those tax and share-count assumptions; this is the sensitivity to test when royalty expectations are updated.

Twelve-month valuation. We continue to value FY2026 business EPS, keeping the earnings period and 8.5–9.5 times multiple unchanged. At an assumed $1.15 per euro and one ADS representing half an ordinary share, €9.00 × 8.5–9.5 × 1.15 ÷ 2 gives $43.99–$49.16. The $46.58 midpoint implies 5.0% price upside from the $44.34 reaction close. Our assumed €4.20 next annual dividend, modestly above the last €4.12 payment, adds about $2.42 per ADS or 5.4% before withholding tax and fees. Prospective gross total return is approximately 10.5%.

The increase from July’s $42–$47 range comes from the earnings revision, not a new premium for unapproved drugs. We judge roughly 10% expected total return to be market-like over the same twelve months, rather than clear prospective outperformance of the S&P 500. That judgment is conditional on the dividend and exchange-rate assumptions and is not a forecast of a precise index return.

Downside. If business EPS falls back to €8.50, the multiple compresses to 7.5 times and the euro weakens to $1.10, fair value is about $35.06 per ADS, 20.9% below the reaction close. A maintained €4.12 dividend would reduce the gross total-return loss to approximately 15.8%. This scenario is credible if pricing benefits fade faster than expected, royalty offsets disappoint or an expensive acquisition adds risk before generating cash.

What changes our view. A December plan with a credible, quantified post-2031 earnings bridge, a reasonably priced commercial acquisition or convincing clinical differentiation would support revisiting the multiple. Further delays, a material spending commitment without attractive returns, or failure to expand 2027 margins under the existing-business case would weaken the earnings support for Hold. Merely repeating the 2030 sales ambition would not resolve those tests.

Thesis Scorecard Post-Earnings

Overall: The standing thesis is stronger on operating execution and modestly better on strategic credibility. July’s alliance negotiation and missing 2027 margin commitment now have concrete answers, while the vaccines decline was less severe than expected. The remaining gating issue is unchanged: early-stage assets and a cash-preservation ambition do not establish what shareholders earn after Dupixent exclusivity. No pillar status changes this quarter.

Action: Maintain Hold. The earnings increase supports a higher fair-value range and a durable dividend, but the midpoint return remains market-like against a meaningful downside case. We will reassess after the promised December strategy detail, grading the replacement economics, acquisition discipline and clinical timetable rather than the breadth of the presentation.